Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T29024
(Former ID: TTDC00325)
|
|||||
| Target Name |
SOD1 messenger RNA (SOD1 mRNA)
|
|||||
| Synonyms |
hSod1 (mRNA); Superoxide dismutase [Cu-Zn] (mRNA); Superoxide dismutase 1 (mRNA); Superoxide dismutase (mRNA)
Click to Show/Hide
|
|||||
| Gene Name |
SOD1
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Motor neuron disease [ICD-11: 8B60] | |||||
| Function |
Destroys radicals which are normally produced within the cells and which are toxic to biological systems.
Click to Show/Hide
|
|||||
| BioChemical Class |
mRNA target
|
|||||
| UniProt ID | ||||||
| EC Number |
EC 1.15.1.1
|
|||||
| Sequence |
MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTS
AGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVV HEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 1 Approved Drugs | + | ||||
| 1 | Tofersen | Drug Info | Approved | Amyotrophic lateral sclerosis | [2] | |
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | ISIS-SOD1 | Drug Info | Phase 1 | Motor neurone disease | [3] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Inhibitor | [+] 1 Inhibitor drugs | + | ||||
| 1 | Tofersen | Drug Info | [4] | |||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| BioCyc | [+] 1 BioCyc Pathways | + | ||||
| 1 | Reactive oxygen species degradation | |||||
| KEGG Pathway | [+] 4 KEGG Pathways | + | ||||
| 1 | Peroxisome | |||||
| 2 | Amyotrophic lateral sclerosis (ALS) | |||||
| 3 | Huntington's disease | |||||
| 4 | Prion diseases | |||||
| NetPath Pathway | [+] 1 NetPath Pathways | + | ||||
| 1 | TCR Signaling Pathway | |||||
| Pathwhiz Pathway | [+] 1 Pathwhiz Pathways | + | ||||
| 1 | Degradation of Superoxides | |||||
| PID Pathway | [+] 2 PID Pathways | + | ||||
| 1 | Validated nuclear estrogen receptor alpha network | |||||
| 2 | FOXA1 transcription factor network | |||||
| Reactome | [+] 2 Reactome Pathways | + | ||||
| 1 | Platelet degranulation | |||||
| 2 | Detoxification of Reactive Oxygen Species | |||||
| WikiPathways | [+] 10 WikiPathways | + | ||||
| 1 | Oxidative Stress | |||||
| 2 | Copper homeostasis | |||||
| 3 | Detoxification of Reactive Oxygen Species | |||||
| 4 | Nifedipine Activity | |||||
| 5 | Amyotrophic lateral sclerosis (ALS) | |||||
| 6 | Dopamine metabolism | |||||
| 7 | AGE/RAGE pathway | |||||
| 8 | Folate Metabolism | |||||
| 9 | Vitamin B12 Metabolism | |||||
| 10 | Selenium Micronutrient Network | |||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). | |||||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215887. | |||||
| REF 3 | ClinicalTrials.gov (NCT01041222) Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations. U.S. National Institutes of Health. | |||||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 5 | US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.